CRNX Crinetics Pharmaceuticals, Inc. - Common Stock
$84.77
Price · Aug 19, 2026
Fundamentals as of Aug 3, 2026
52W Range
$29–$85
100% of range
Analyst Rating
HOLD
21 analysts
Price Target
$86
+1% upside
P/E (TTM)
-17.1
ROE
-43.0%
Net Profit Margin
-6046.2%
About Crinetics Pharmaceuticals, Inc. - Common Stock Company overview from Wikipedia
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
Read more
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
In July 2026, Vertex Pharmaceuticals agreed to acquire the company for $10 billion.
History
Struthers, Zhu, Kusnetzow, and Betz founded Crinetics in 2008 after previously working together on a small molecule drug for the treatment of endometriosis at Neurocrine Biosciences.
Crinetics expanded into a larger laboratory in 2010. After receiving NIH grant funding, Crinetics moved into its second laboratory.
In 2011, Crinetics Pharmaceuticals competed for the Michelson Prize, a competition sponsored by the Found Animals Foundation to develop a low-cost, non-surgical method for sterilizing dogs and cats, which would later lead to the licensing of a molecule for the treatment of acromegaly in large breed dogs.
Crinetics first synthesized its lead drug candidate to treat acromegaly. The drug was named paltusotine, in 2016. Crinetics Pharmaceuticals went public with an IPO in 2018. It conducted Phase II trials for paltusotine from 2019 to 2020. It conducted Phase III trials for paltusotine from 2021 to 2024. After the drug succeeded in a second Phase III study, the FDA accepted the company's new drug application for paltusotine and the company announced it was planning for a 2025 launch for the drug. The FDA set a Prescription Drug User Fee Act for the drug on September 25, 2025.
In 2021, Crinetics, together with 5AM Ventures and Frazier Healthcare Partners, formed an independently operated new company, Radionetics Oncology, aimed to develop a deep pipeline of novel, targeted, nonpeptide radiopharmaceuticals for the treatment of a broad range of oncology indications.
Crinetics partnered with the veterinary medicine company Loyal to develop a pill to extend the lifespans of large dogs in 2023.
In 2024, Scott Struthers received the Ernst & Young Entrepreneur of the Year Award for his work with Crinetics. In 2024, Crinetics was reported to have patent activity in rare diseases, health technology, and addiction therapies.
In 2024, Radionetics formed a strategic relationship with Eli Lilly and Company to take forward Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals. Under the terms of the agreement, Radionetics received a $140 million upfront cash payment. As part of the strategic agreement, Lilly obtained the exclusive right to acquire Radionetics upon conclusion of an exercise period for $1 billion.
Crinetics also established its first office outside the United States in Zug, Switzerland in 2024.
In 2025, Crinetics Pharmaceuticals plans to file an Investigational New Drug for an oral thyroid stimulating hormone receptor antagonist and its nonpeptide drug conjugate (CRN09682). A total of four development candidates are currently in IND-enabling studies, including a PTH antagonist (Hyperparathyrodism), non-peptide drug conjugate (NETs and SST2-expressing solid tumors), TSH antagonist (Graves’ disease & TED) and SST3 agonist (ADPKD).
In July 2026, Vertex Pharmaceuticals agreed to acquire Crinetics for $10 billion.
Treatments
Crinetics’ pipeline focuses on synthesizing novel molecules for rare endocrine diseases. It is most known for developing paltusotine, a drug designed to treat the hormonal disorder acromegaly. Paltusotine works by helping moderate elevated IGF-1 levels, which is the main symptom of acromegaly. Paltusotine has also been tested as a treatment for carcinoid syndrome.
Crinetics has also developed oral treatments for neuroendocrine tumors, hyperinsulism, and Cushing's disease. The company's drug for treating Cushing's disease, Atumeltnant (also known as CRN049894), works by reducing levels of ACTH.
The company's pipeline also includes an oral parathyroid hormone inhibitor program for hyperparathyroidism and treatments for thyroid eye disease, Graves' disease, and obesity. Additionally, Crinetics nonpeptide drug conjugates (NDCs) include CRN09682, which is a somatostatin receptor 2 (SST2) targeted drug. NDCs are a new technology developed in-house by Crinetics.
== References ==
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
CRNX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$84.77
Market Cap
$8.10B
P/E (TTM)
-17.1
EPS (TTM)
$-4.95
Revenue (TTM)
$8M
Div Yield
—
ROE
-43.0%
Debt/Equity
—
52W Range
$29 – $85
CRNX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
$8M
2016-12-31
→
2025-12-31
EPS
$-4.95
2020-12-31
→
2025-12-31
Free Cash Flow
$-384M
2018-12-31
→
2025-12-31
Margins
-6046.2%
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
CRNX
Peer Median
P/E (TTM)
-17.1
47.9
P/S (TTM)
1052.7
16.2
P/B
8.2
9.3
Price / FCF
-21.1
—
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
CRNX
Peer Median
Operating Margin
-6714.8%
—
Net Profit Margin
-6046.2%
5.1%
ROA
-36.3%
0.81%
ROE
-43.0%
-15.3%
ROIC
-52.1%
—
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
CRNX
Peer Median
Current Ratio
12.3
2.7
Quick Ratio
12.1
—
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
CRNX
Peer Median
Revenue YoY
640.7%
—
Revenue CAGR 3Y
17.6%
—
Revenue CAGR 5Y
155.3%
—
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
CRNX
Peer Median
CRNX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
HOLD
21 analysts
- Strong Buy 3 14.3%
- Buy 4 19.0%
- Hold 14 66.7%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
10 analysts · 2026-08-13
Median
$85.00
Mean
$85.50
← Below all targets
$84.77
Low
$85.00
High
$90.00
Median target
$85.00
+0.3%
Mean target
$85.50
+0.9%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-0.01%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| June 30, 2026 | $-1.14 | $-1.23 | 0.09% |
| March 31, 2026 | $-1.23 | $-1.26 | 0.03% |
| Dec. 31, 2025 | $-1.29 | $-1.39 | 0.10% |
| Sept. 30, 2025 | $-1.38 | $-1.28 | -0.10% |
| June 30, 2025 | $-1.23 | $-1.12 | -0.11% |
| March 31, 2025 | $-1.04 | $-0.96 | -0.08% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| CRNX | $4.45B | -9.4 | 640.7% | -6046.2% | -43.0% | — |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
| AXSM | $9.29B | -49.6 | 65.5% | -28.7% | -227.0% | — |
| LQDA | $3.01B | -43.1 | 1031.2% | -43.5% | -230.0% | — |
| BLTE | — | — | — | — | — | — |
| DFTX | $1.32B | -6.5 | 212.0% | — | -71.0% | — |
| LGND | $3.74B | 30.8 | 60.4% | 46.4% | 13.5% | — |
| AMRX | — | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 17
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | $2M | |
| Cost of Revenue | $1M | $0 | $0 | · | · | · | · | · | · | |
| R&D Expense | $332M | $240M | $169M | $130M | $84M | $57M | $42M | $24M | $9M | |
| SG&A Expense | $191M | $100M | $58M | $42M | $25M | $18M | $14M | $7M | $2M | |
| Operating Expenses | $524M | $340M | $227M | $173M | $109M | $75M | $55M | $31M | $11M | |
| Operating Income | $-517M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | $-9M | |
| Interest Expense | · | · | · | · | · | · | · | · | $8.0K | |
| Interest Income | $52M | $41M | $13M | $4M | $157.0K | $991.0K | $3M | $2M | $26.0K | |
| Other Non-op | $-357.0K | $-519.0K | $-159.0K | $5M | $61.0K | $1M | $3M | $2M | $-30.0K | |
| Pretax Income | $-465M | $-298M | $-209M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| Income Tax | $180.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| EPS (Basic) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| EPS (Diluted) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| Shares (Basic) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| Shares (Diluted) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| EBITDA | $-513M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | · |
Balance Sheet 24
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $102M | $265M | $55M | $33M | $201M | $93M | $40M | $45M | $14M | |
| Short-term Investments | $926M | $1.09B | $504M | $302M | $133M | $78M | $78M | $119M | · | |
| Receivables | $592.0K | $0 | · | · | · | · | · | · | · | |
| Inventory | $2M | $0 | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $21M | $16M | $11M | $11M | $7M | $5M | $3M | $973.0K | |
| Other Current Assets | $3M | $2M | $448.0K | $2M | $912.0K | $1M | $668.0K | $876.0K | $239.0K | |
| Current Assets | $1.05B | $1.38B | $574M | $345M | $345M | $177M | $123M | $167M | $15M | |
| PP&E (Net) | $14M | $12M | $11M | $4M | $3M | $3M | $4M | $4M | $400.0K | |
| PP&E (Gross) | $22M | $20M | $16M | $8M | $6M | $6M | $6M | $5M | $704.0K | |
| Accum. Depreciation | $8M | $8M | $5M | $4M | $3M | $3M | $2M | $741.0K | $304.0K | |
| Other Non-current Assets | · | $3M | $2M | $37.0K | $0 | $40.0K | $82.0K | · | $33.0K | |
| Total Assets | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Accounts Payable | $23M | $6M | $7M | $7M | $3M | $6M | $5M | $5M | $403.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | $4M | $179.0K | |
| Current Liabilities | $85M | $60M | $44M | $28M | $16M | $10M | $8M | $8M | $897.0K | |
| Capital Leases | $42M | $45M | $48M | $2M | $3M | $4M | $5M | · | · | |
| Other Non-current Liabilities | $3M | $829.0K | $0 | · | · | · | · | · | · | |
| Total Liabilities | $134M | $110M | $96M | $36M | $19M | $15M | $13M | $11M | $920.0K | |
| Common Stock | · | · | $253.0K | $0 | · | · | · | $24.0K | $1.0K | |
| Retained Earnings | $-1.42B | $-952M | $-654M | $-439M | $-275M | $-168M | $-94M | $-43M | $-16M | |
| AOCI | $2M | $963.0K | $977.0K | $-4M | $-382.0K | $25.0K | $148.0K | $61.0K | · | |
| Stockholders' Equity | $992M | $1.32B | $539M | $316M | $332M | $169M | $117M | $160M | $-15M | |
| Liabilities + Equity | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Shares Outstanding | 95,575,000 | 92,926,000 | 68,175,000 | 53,877,000 | 47,597,000 | 33,001,000 | 24,263,000 | 24,061 | 1,549,575 |
Cash Flow 13
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $1M | $983.0K | $922.0K | $948.0K | $887.0K | $471.0K | $128.0K | |
| Stock-based Comp | $91M | $69M | $41M | $28M | $17M | $10M | $6M | $2M | $271.0K | |
| Deferred Tax | $0 | $0 | $0 | · | · | · | · | · | · | |
| Other Non-cash | $-8M | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-378M | $-230M | $-169M | $-115M | $-89M | $-62M | $-46M | $-19M | $-9M | |
| CapEx | $6M | $4M | $5M | $2M | $436.0K | $186.0K | $492.0K | $1M | $304.0K | |
| Investing Cash Flow | $174M | $-575M | $-200M | $-174M | $-56M | $217.0K | $42M | $-119M | $-304.0K | |
| Stock Issued | $0 | $985M | $370M | $117M | $250M | $114M | · | $106M | · | |
| Net Stock Activity | $0 | $970M | $369M | $117M | $250M | $114M | · | · | · | |
| Financing Cash Flow | $41M | $1.01B | $391M | $122M | $253M | $115M | $67.0K | $170M | $12M | |
| Net Change in Cash | · | $210M | $22M | $-167M | $108M | $53M | $-5M | $31M | $2M | |
| Taxes Paid | $89.0K | $0 | $0 | · | · | · | · | · | · | |
| Free Cash Flow | $-384M | $-230M | $-171M | $-117M | $-89M | $-62M | $-47M | $-21M | · |
Profitability 7
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| Net Margin | -6046.2% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| Pretax Margin | -6043.9% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| EBITDA Margin | -6664.1% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| ROA | -36.3% | -28.8% | -43.5% | -46.6% | -40.3% | -47.0% | -33.4% | -29.0% | · | |
| ROE | -43.0% | -27.7% | -39.5% | -49.1% | -41.0% | -41.4% | -40.9% | -16.6% | · | |
| ROIC | -52.1% | -25.6% | -41.3% | -53.1% | -32.5% | -44.4% | -46.0% | -17.9% | · |
Liquidity & Solvency 2
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 | 16.9 | 14.8 | 21.0 | · | |
| Quick Ratio | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 | 16.3 | 14.2 | 20.7 | · |
Efficiency 3
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | |
| Inventory Turnover | 1.1 | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 26.0 | · | · | · | · | · | · | · | · |
Growth Rates 3
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 640.7% | -74.1% | -15.3% | 339.4% | 1418.3% | · | · | · | · | |
| Revenue CAGR 3Y | 17.6% | -1.2% | 283.8% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 155.3% | · | · | · | · | · | · | · | · |
Valuation (TTM) 10
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | · | |
| Net Income TTM | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | · | |
| Market Cap | $4.45B | $4.75B | $2.43B | $986M | $1.35B | $466M | $608.8K | $722M | · | |
| P/E | -9.4 | -13.9 | -9.6 | -5.8 | -10.1 | -5.8 | · | · | · | |
| P/S | 578.1 | 4573.0 | 604.5 | 208.1 | 1254.4 | 6558.4 | 0.5 | 297.2 | · | |
| P/B | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | 0.0 | 4.5 | · | |
| P / Tangible Book | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | · | · | · | |
| P / Cash Flow | -11.8 | -21.0 | -14.6 | -8.6 | -15.3 | -7.5 | -0.0 | -37.1 | · | |
| P / FCF | -11.6 | -20.7 | -14.2 | -8.4 | -15.2 | -7.5 | -0.0 | -35.2 | · | |
| Earnings Yield | -10.6% | -7.2% | -10.4% | -17.2% | -9.9% | -17.2% | · | · | · |
Income Statement 15
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25M | $11M | $6M | $143.0K | $1M | $361.0K | $0 | $0 | $399.0K | $640.0K | $0 | $346.0K | $988.0K | $3M | $709.0K | $458.0K | |
| Cost of Revenue | $154.0K | $200.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| R&D Expense | $100M | $100M | $85M | $90M | $80M | $76M | $67M | $62M | $58M | $53M | $46M | $44M | $41M | $38M | $37M | $32M | |
| SG&A Expense | $58M | $51M | $54M | $52M | $50M | $36M | $28M | $26M | $25M | $21M | $17M | $15M | $13M | $12M | $11M | $12M | |
| Operating Expenses | $158M | $151M | $140M | $143M | $130M | $112M | $95M | $88M | $83M | $74M | $63M | $59M | $54M | $51M | $48M | $44M | |
| Operating Income | $-132M | $-140M | $-134M | $-143M | $-129M | $-111M | $-95M | $-88M | $-83M | $-74M | $-63M | $-59M | $-53M | $-48M | $-48M | $-43M | |
| Interest Income | $12M | $13M | $11M | $13M | $13M | $15M | $14M | $11M | $9M | $7M | $7M | $3M | $2M | $2M | $2M | $2M | |
| Other Non-op | $-423.0K | $-131.0K | $-28M | $-49.0K | $20.0K | $-203.0K | $-16M | $-37.0K | $9M | $7M | $-7M | $3M | $2M | $2M | $3M | $2M | |
| Pretax Income | · | · | $-123M | $-130M | · | · | $-81M | $-77M | · | · | · | · | · | · | · | · | |
| Net Income | $-121M | $-128M | $-123M | $-130M | $-116M | $-97M | $-81M | $-77M | $-74M | $-67M | $-60M | $-57M | $-51M | $-46M | $-45M | $-42M | |
| EPS (Basic) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| EPS (Diluted) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| Shares (Basic) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| Shares (Diluted) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| EBITDA | $-132M | $-140M | · | $-143M | $-129M | $-111M | · | $-88M | $-83M | $-74M | · | $-59M | $-53M | $-48M | · | $-43M |
Balance Sheet 23
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $55M | $114M | $102M | $111M | $54M | $95M | $265M | $317M | $302M | $396M | $55M | $143M | $40M | $41M | $33M | $31M | |
| Short-term Investments | $1.15B | $1.18B | $926M | $981M | $1.14B | $1.18B | $1.09B | $545M | $561M | $505M | · | $412M | $225M | $255M | · | $337M | |
| Receivables | $12M | $6M | $592.0K | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Inventory | $3M | $3M | $2M | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $23M | $22M | $18M | $28M | $20M | $16M | $21M | $15M | $12M | $16M | · | $21M | $20M | $9M | · | $10M | |
| Other Current Assets | $5M | $6M | $3M | $5M | $4M | $3M | $2M | $1M | $2M | $4M | · | $4M | $3M | $3M | · | $2M | |
| Current Assets | $1.24B | $1.32B | $1.05B | $1.12B | $1.22B | $1.29B | $1.38B | $878M | $875M | $917M | · | $576M | $285M | $305M | · | $378M | |
| PP&E (Net) | $13M | $13M | $14M | $14M | $15M | $13M | $12M | $12M | $12M | $12M | · | $10M | $3M | $3M | · | $4M | |
| PP&E (Gross) | $23M | $23M | $22M | $21M | $24M | $21M | $20M | $19M | $18M | $17M | · | $15M | $8M | $8M | · | $7M | |
| Accum. Depreciation | $10M | $9M | $8M | $7M | $10M | $9M | $8M | $7M | $6M | $5M | · | $5M | $5M | $4M | · | $4M | |
| Other Non-current Assets | · | · | · | · | · | $14M | · | $3M | $2M | $2M | · | $2M | $2M | $2M | · | · | |
| Total Assets | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Accounts Payable | $13M | $13M | $23M | $6M | $11M | $10M | $6M | $5M | $9M | $11M | · | $6M | $5M | $6M | · | $6M | |
| Current Liabilities | $80M | $71M | $85M | $74M | $68M | $57M | $60M | $54M | $54M | $52M | · | $40M | $33M | $26M | · | $25M | |
| Capital Leases | $41M | $41M | $42M | $43M | $43M | $44M | $45M | $45M | $46M | $47M | · | $48M | $1M | $2M | · | $2M | |
| Other Non-current Liabilities | $6M | $5M | $3M | $3M | $2M | $2M | $829.0K | $511.0K | $202.0K | · | · | · | · | · | · | · | |
| Total Liabilities | $130M | $121M | $134M | $124M | $118M | $107M | $110M | $104M | $105M | $103M | · | $94M | $39M | $34M | · | $34M | |
| Common Stock | · | · | · | · | · | · | · | · | · | $881.0K | · | · | · | · | · | · | |
| Retained Earnings | $-1.67B | $-1.55B | $-1.42B | $-1.29B | $-1.16B | $-1.05B | $-952M | $-872M | $-795M | $-721M | · | $-594M | $-536M | $-485M | · | $-394M | |
| AOCI | $-3M | $-1M | $2M | $2M | $2M | $2M | $963.0K | $2M | $-190.0K | $150.0K | · | $-865.0K | $-2M | $-3M | · | $-5M | |
| Stockholders' Equity | $1.19B | $1.28B | $992M | $1.07B | $1.17B | $1.25B | $1.32B | $833M | $831M | $875M | $539M | $548M | $254M | $280M | $316M | $351M | |
| Liabilities + Equity | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Shares Outstanding | 105,808,000 | 105,314,000 | 95,575,000 | 94,548,000 | 94,126,000 | 93,525,000 | 92,926,000 | 80,841,000 | 79,322,000 | 78,539,000 | · | 66,708,000 | 54,682,000 | 53,990,000 | · | 53,796,000 |
Cash Flow 10
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $994.0K | $1M | $959.0K | $925.0K | $788.0K | $770.0K | $753.0K | $474.0K | $262.0K | $273.0K | $280.0K | $283.0K | $280.0K | $248.0K | |
| Stock-based Comp | $25M | $30M | $22M | $23M | $26M | $20M | $19M | $18M | $19M | $13M | $12M | $11M | $10M | $8M | $8M | $7M | |
| Operating Cash Flow | $-94M | $-125M | $-93M | $-111M | $-86M | $-88M | $-67M | $-65M | $-48M | $-53M | $-41M | $-41M | $-46M | $-41M | $-35M | $-38M | |
| CapEx | $521.0K | $820.0K | $458.0K | $863.0K | $3M | $1M | $1M | $528.0K | $955.0K | $1M | $935.0K | $4M | $237.0K | $16.0K | $274.0K | $682.0K | |
| Investing Cash Flow | $26M | $-252M | $57M | $165M | $38M | $-86M | $-542M | $21M | $-54M | $309.0K | $-87M | $-193M | $31M | $49M | $37M | $7M | |
| Stock Issued | $0 | $381M | $0 | $0 | $0 | $0 | $544M | $63M | $10M | $383M | $29M | $329M | $11M | $0 | $0 | $-13.0K | |
| Net Stock Activity | · | $381M | · | · | · | $0 | · | · | · | $383M | · | · | · | · | · | · | |
| Financing Cash Flow | $9M | $390M | $26M | $3M | $7M | $4M | $556M | $59M | $8M | $394M | $40M | $338M | $13M | $484.0K | $115.0K | $1M | |
| Net Change in Cash | · | · | · | $57M | $-41M | $-170M | · | $15M | $-94M | $341M | · | $103M | $-2M | $9M | $2M | $-31M | |
| Free Cash Flow | · | $-126M | · | · | · | $-90M | · | · | · | $-54M | · | · | · | $-41M | · | · |
Profitability 6
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| Net Margin | -481.1% | -1191.0% | · | -90972.7% | -11216.0% | -26807.2% | · | · | -18560.1% | -10457.8% | · | -16606.4% | -5159.8% | -1716.9% | · | -9153.9% | |
| Pretax Margin | · | · | · | -90972.7% | · | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| ROA | -9.3% | -9.3% | · | -12.2% | -10.4% | -8.3% | · | -9.7% | -12.0% | -10.4% | · | -11.2% | -14.3% | -14.2% | · | -14.1% | |
| ROE | -10.2% | -10.1% | · | -13.7% | -11.6% | -9.1% | · | -11.1% | -13.7% | -11.6% | · | -12.8% | -15.9% | -15.8% | · | -15.4% |
Liquidity & Solvency 2
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.6 | 18.6 | · | 15.1 | 17.8 | 22.5 | · | 16.4 | 16.1 | 17.7 | · | 14.2 | 8.7 | 11.6 | · | 15.4 | |
| Quick Ratio | 15.2 | 18.2 | · | 14.7 | 17.5 | 22.2 | · | 16.1 | 15.9 | 17.4 | · | 13.7 | 8.1 | 11.3 | · | 15.0 |
Efficiency 3
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.1 | 0.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 4.2 | 3.8 | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM) 10
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $37M | $12M | · | $2M | $2M | $1M | · | $1M | $2M | $5M | · | $4M | $5M | $7M | · | $4M | |
| Net Income TTM | $-494M | $-470M | · | $-419M | $-363M | $-315M | · | $-275M | $-249M | $-221M | · | $-196M | $-181M | $-165M | · | $-147M | |
| Market Cap | $3.96B | $3.83B | · | $3.94B | $2.71B | $3.14B | · | $4.13B | $3.55B | $3.68B | · | $1.98B | $985M | $867M | · | $1.06B | |
| P/E | -7.5 | -7.4 | · | -9.0 | -6.9 | -8.7 | · | -13.3 | -11.7 | -12.5 | · | -8.3 | -5.3 | -5.1 | · | -6.4 | |
| P/S | 106.9 | 311.8 | · | 2565.4 | 1511.5 | 2240.6 | · | 2982.7 | 1497.2 | 790.1 | · | 443.7 | 215.9 | 129.3 | · | 262.3 | |
| P/B | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Tangible Book | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Cash Flow | · | -30.7 | · | · | · | -35.5 | · | · | · | -69.6 | · | · | · | -21.3 | · | · | |
| P / FCF | · | -30.5 | · | · | · | -35.0 | · | · | · | -67.8 | · | · | · | -21.3 | · | · | |
| Earnings Yield | -13.3% | -13.4% | · | -11.1% | -14.5% | -11.5% | · | -7.5% | -8.5% | -8.0% | · | -12.0% | -18.8% | -19.7% | · | -15.5% |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenue | $8M | $1M | $4M | $5M | $1M |
| Operating Margin % | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% |
| Net Income | $-465M | $-298M | $-215M | $-164M | $-108M |
| Diluted EPS | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 |
Balance Sheet
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Current Ratio | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 |
| Quick Ratio | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 |
Cash Flow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Free Cash Flow | $-384M | $-230M | $-171M | $-117M | $-89M |
Latest News Recent headlines mentioning this company
- Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal
- Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
- Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
- Why This Pharmaceutical Stock Jumped Close to 100% This Week
- Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 286 filers · $3.2B total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 63 (+17 vs prior Q) | 30 (-14 vs prior Q) | 95 (-17 vs prior Q) | 63 (+3 vs prior Q) | +21.6M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| FMR LLC | $486,250,673 | 12,994,406 | 15.13% | Shares |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $336,372,047 | 8,989,098 | 10.46% | Shares |
| Driehaus Capital Management LLC | $241,866,078 | 6,463,551 | 7.52% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $237,002,526 | 6,333,579 | 7.37% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $180,836,416 | 4,832,614 | 5.63% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $177,567,704 | 4,745,262 | 5.52% | Shares |
| STATE STREET CORP | $100,635,477 | 2,689,350 | 3.13% | Shares |
| Bellevue Group AG | $98,040,400 | 2,620,000 | 3.05% | Shares |
| BAKER BROS. ADVISORS LP | $87,991,820 | 2,351,465 | 2.74% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $87,542,675 | 2,338,905 | 2.72% | Shares |
| Polar Capital Holdings Plc | $85,108,460 | 2,274,411 | 2.65% | Shares |
| Pictet Asset Management Holding SA | $77,572,984 | 2,075,375 | 2.41% | Shares |
| Siren, L.L.C. | $53,165,887 | 1,420,788 | 1.65% | Shares |
| First Light Asset Management, LLC | $50,923,606 | 1,360,866 | 1.58% | Shares |
| NOVO HOLDINGS A/S | $49,394,400 | 1,320,000 | 1.54% | Shares |
| AMERICAN CENTURY COMPANIES INC | $47,245,129 | 1,262,562 | 1.47% | Shares |
| ADAR1 Capital Management, LLC | $45,730,234 | 1,222,080 | 1.42% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $44,555,208 | 1,190,679 | 1.39% | Shares |
| MONTANOVA CAPITAL, LLC | $44,390,560 | 1,186,279 | 1.38% | Shares |
| ORBIMED ADVISORS LLC | $37,382,580 | 999,000 | 1.16% | Shares |
| Hood River Capital Management LLC | $36,259,830 | 968,996 | 1.13% | Shares |
| GOLDMAN SACHS GROUP INC | $34,657,132 | 926,166 | 1.08% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $32,841,401 | 877,643 | 1.02% | Shares |
| Aberdeen Group plc | $30,699,181 | 820,395 | 0.95% | Shares |
| Candriam S.C.A. | $30,618,690 | 819,032 | 0.95% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $28,230,995 | 754,436 | 0.88% | Shares |
| Fisher Asset Management, LLC | $27,748,912 | 741,553 | 0.86% | Shares |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $17,709,036 | 479,400 | 0.55% | Shares |
| AMERIPRISE FINANCIAL INC | $17,451,149 | 466,356 | 0.54% | Shares |
| Impax Asset Management Group plc | $16,277,700 | 435,000 | 0.51% | Shares |
| Prosight Management, LP | $14,020,002 | 374,666 | 0.44% | Shares |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $13,991,714 | 373,910 | 0.44% | Shares |
| KENNEDY CAPITAL MANAGEMENT LLC | $13,685,018 | 365,714 | 0.43% | Shares |
| BRAUN STACEY ASSOCIATES INC | $13,027,511 | 348,143 | 0.41% | Shares |
| Fiera Capital Corp | $12,395,263 | 331,247 | 0.39% | Shares |
| BANK OF AMERICA CORP /DE/ | $11,271,877 | 301,226 | 0.35% | Shares |
| Defilade Capital Management, L.P. | $8,959,845 | 239,440 | 0.28% | Shares |
| SEB Asset Management AB | $8,003,786 | 213,891 | 0.25% | Shares |
| Foresite Capital Management VI LLC | $7,933,414 | 212,010 | 0.25% | Shares |
| RICE HALL JAMES & ASSOCIATES, LLC | $7,346,220 | 196,318 | 0.23% | Shares |
| TD Asset Management Inc | $7,152,534 | 191,142 | 0.22% | Shares |
| Swiss National Bank | $6,877,796 | 183,800 | 0.21% | Shares |
| SEGALL BRYANT & HAMILL, LLC | $6,855,307 | 183,199 | 0.21% | Shares |
| BlackRock, Inc. | $6,781,290 | 181,221 | 0.21% | Shares |
| JENNISON ASSOCIATES LLC | $6,056,839 | 161,861 | 0.19% | Shares |
| New Leaf Venture Partners, L.L.C. | $5,872,650 | 141,000 | 0.18% | Shares |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $5,865,136 | 156,738 | 0.18% | Shares |
| Foresite Capital Management IV, LLC | $5,613,000 | 150,000 | 0.17% | Shares |
| Bank of New York Mellon Corp | $5,581,754 | 149,165 | 0.17% | Shares |
| NEW YORK STATE COMMON RETIREMENT FUND | $5,508,898 | 147,218 | 0.17% | Shares |
| ENVESTNET ASSET MANAGEMENT INC | $5,471,384 | 146,216 | 0.17% | Shares |
| Moody Aldrich Partners LLC | $5,466,201 | 146,077 | 0.17% | Shares |
| Ishara Investments LP | $5,369,770 | 143,500 | 0.17% | Shares |
| CITADEL ADVISORS LLC | $5,176,271 | 138,329 | 0.16% | Shares |
| RHUMBLINE ADVISERS | $4,861,141 | 129,908 | 0.15% | Shares |
| ALLIANCEBERNSTEIN L.P. | $4,782,618 | 131,680 | 0.15% | Shares |
| GordonMD Global Investments LP | $4,751,779 | 126,985 | 0.15% | Shares |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $4,712,974 | 125,948 | 0.15% | Shares |
| JANUS HENDERSON GROUP PLC | $4,700,428 | 129,392 | 0.15% | Shares |
| Cormorant Asset Management, LP | $4,677,500 | 125,000 | 0.15% | Shares |
| SECTOR GAMMA AS | $4,289,380 | 114,628 | 0.13% | Shares |
| XTX Topco Ltd | $4,164,547 | 111,292 | 0.13% | Shares |
| ALPS ADVISORS INC | $3,981,825 | 106,409 | 0.12% | Shares |
| FEDERATED HERMES, INC. | $3,957,390 | 105,756 | 0.12% | Shares |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $3,834,048 | 105,563 | 0.12% | Shares |
| Nuveen Asset Management, LLC | $3,760,151 | 73,541 | 0.12% | Shares |
| Burkehill Global Management, LP | $3,742,000 | 100,000 | 0.12% | Shares |
| Nuveen, LLC | $3,619,262 | 96,720 | 0.11% | Shares |
| VICTORY CAPITAL MANAGEMENT INC | $3,484,251 | 93,112 | 0.11% | Shares |
| MORGAN STANLEY | $3,320,829 | 88,744 | 0.10% | Shares |
| TWO SIGMA INVESTMENTS, LP | $3,266,729 | 87,299 | 0.10% | Shares |
| VANGUARD ASSET MANAGEMENT, Ltd | $3,254,754 | 86,979 | 0.10% | Shares |
| AWM Investment Company, Inc. | $3,180,700 | 85,000 | 0.10% | Shares |
| Odyssean, LLC | $3,160,344 | 84,456 | 0.10% | Shares |
| Affinity Asset Advisors, LLC | $2,806,500 | 75,000 | 0.09% | Shares |
| ALGERT GLOBAL LLC | $2,714,147 | 72,532 | 0.08% | Shares |
| ExodusPoint Capital Management, LP | $2,652,404 | 70,882 | 0.08% | Shares |
| Ensign Peak Advisors, Inc | $2,507,290 | 67,004 | 0.08% | Shares |
| BARCLAYS PLC | $2,466,127 | 65,904 | 0.08% | Shares |
| FIRST TRUST ADVISORS LP | $2,370,631 | 63,352 | 0.07% | Shares |
| Man Group plc | $2,284,229 | 61,043 | 0.07% | Shares |
| MetLife Investment Management, LLC | $2,258,709 | 60,361 | 0.07% | Shares |
| CITIGROUP INC | $2,255,229 | 60,268 | 0.07% | Shares |
| Longaeva Partners L.P. | $2,184,879 | 58,388 | 0.07% | Shares |
| Swedbank AB | $2,155,392 | 57,600 | 0.07% | Shares |
| STATE OF WISCONSIN INVESTMENT BOARD | $2,068,016 | 55,265 | 0.06% | Shares |
| Jump Financial, LLC | $1,923,388 | 51,400 | 0.06% | Shares |
| Lighthouse Investment Partners, LLC | $1,871,000 | 50,000 | 0.06% | Shares |
| Vestmark Advisory Solutions, Inc. | $1,823,252 | 48,724 | 0.06% | Shares |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $1,787,254 | 47,762 | 0.06% | Shares |
| VANGUARD GROUP INC | $1,774,626 | 38,123 | 0.06% | Shares |
| Point72 Asset Management, L.P. | $1,735,577 | 46,381 | 0.05% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $1,696,398 | 45,334 | 0.05% | Shares |
| RAYMOND JAMES FINANCIAL INC | $1,606,254 | 42,925 | 0.05% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,549,188 | 41,400 | 0.05% | Call option |
| Invesco Ltd. | $1,545,446 | 41,300 | 0.05% | Shares |
| Vanguard Global Advisers, LLC | $1,485,986 | 39,711 | 0.05% | Shares |
| HighMark Wealth Management LLC | $1,444,224 | 38,595 | 0.04% | Shares |
| OAK RIDGE INVESTMENTS LLC | $1,405,046 | 37,548 | 0.04% | Shares |
| Orion Porfolio Solutions, LLC | $1,404,234 | 37,526 | 0.04% | Shares |
Company insiders 20 insiders · 9 officers · 10 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Tobin Schilke | Chief Financial Officer | March 10, 2025 A | 52,000 | 0 | 0 | $0 |
| Marc Wilson | CFO | Sept. 26, 2024 M | 111,092 | 0 | 0 | $0 |
| Jeff E. Knight | Chief Operating Officer | March 19, 2025 S | 87,491 | 0 | 0 | $0 |
| Stephen F. Betz | Chief Scientific Officer | June 12, 2025 M | 99,713 | 0 | 0 | $0 |
| Dana Pizzuti | Chief Med and Dev Officer | March 19, 2025 S | 72,233 | 0 | 0 | $0 |
| Isabel Kalofonos | Chief Commercial Officer | Jan. 10, 2025 A | — | 0 | 0 | $0 |
| James Hassard | Chief Commercial Officer | July 5, 2024 M | 29,259 | 0 | 0 | $0 |
| Alan Seth Krasner | Chief Medical Officer | Oct. 17, 2023 M | 43,210 | 0 | 0 | $0 |
| Ajay Madan | Chief Development Officer | Feb. 28, 2022 A | 176,995 | 0 | 0 | $0 |
| Coelho Rogerio Vivaldi | Director | July 2, 2026 S | 19,225 | 0 | 1 | $-120,000 |
| Caren Deardorf | Director | June 18, 2026 A | 22,225 | 0 | 0 | $0 |
| Weston Nichols | Director | June 18, 2026 A | 22,225 | 0 | 0 | $0 |
| Stephanie Okey | Director | June 18, 2026 A | 12,325 | 0 | 2 | $-246,143 |
| Matthew K Fust | Director | June 18, 2026 A | 28,761 | 0 | 0 | $0 |
| Camille L Bedrosian | Director | June 18, 2026 A | 22,225 | 0 | 0 | $0 |
| Wendell Wierenga | Director | June 18, 2026 A | 122,071 | 0 | 0 | $0 |
| Wendall Wierenga | Director | June 11, 2025 A | 116,146 | 0 | 0 | $0 |
| Stephen W Kaldor | Director | June 19, 2020 A | — | 0 | 0 | $0 |
| Jack Nielsen | Director | June 21, 2019 A | — | 0 | 0 | $0 |
| Richard Scott Struthers | — | Aug. 7, 2026 M | 424,706 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Perceptive Advisors LLC, Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. ×6 filings | March 1, 2024 | — | Initial filing | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 55 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| SBIO · ALPS ETF Trust | 2.37% | 107,892 NS | May 31, 2026 | N-PORT |
| IHE · iShares Trust | 1.95% | 376,636 SH | Aug. 8, 2026 | Daily |
| FMED · Fidelity Covington Trust | 1.65% | 19,000 NS | May 31, 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1.40% | 4,666 NS | April 30, 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1.23% | 18,743 NS | April 30, 2026 | N-PORT |
| MMSC · First Trust Exchange-Traded Fund VI… | 0.75% | 11,043 NS | May 31, 2026 | N-PORT |
| IBB · iShares Trust | 0.63% | 718,323 SH | Aug. 8, 2026 | Daily |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.60% | 5,737 SH | Aug. 8, 2026 | Daily |
| IWO · iShares Trust | 0.54% | 940,202 SH | Aug. 8, 2026 | Daily |
| NUSC · Nushares ETF Trust | 0.28% | 93,045 NS | April 30, 2026 | N-PORT |
| ISCG · iShares Trust | 0.27% | 32,694 SH | Aug. 8, 2026 | Daily |
| IWM · iShares Trust | 0.27% | 2,625,192 SH | Aug. 8, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.23% | 110,770 SH | Aug. 8, 2026 | Daily |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0.20% | 38,553 NS | April 30, 2026 | N-PORT |
| BIB · ProShares Trust | 0.19% | 3,872 NS | May 31, 2026 | N-PORT |
| ESML · iShares Trust | 0.16% | 55,438 SH | Aug. 8, 2026 | Daily |
| BKSE · BNY Mellon ETF Trust | 0.15% | 3,142 NS | April 30, 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.15% | 51,135 SH | Aug. 8, 2026 | Daily |
| FNY · First Trust Exchange-Traded AlphaDE… | 0.14% | 18,879 NS | April 30, 2026 | N-PORT |
| ISCB · iShares Trust | 0.13% | 4,625 SH | Aug. 8, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.12% | 596,648 SH | Aug. 8, 2026 | Daily |
| RSSL · Global X Funds | 0.12% | 42,391 NS | April 30, 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0.11% | 1,399,667 SH | Aug. 8, 2026 | Daily |
| FFSM · FIDELITY COVINGTON TRUST | 0.10% | 31,759 NS | April 30, 2026 | N-PORT |
| ITWO · ProShares Trust | 0.09% | 4,601 NS | May 31, 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.09% | 2,909 SH | Aug. 8, 2026 | Daily |
| SCHA · SCHWAB STRATEGIC TRUST | 0.08% | 492,431 NS | May 31, 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0.07% | 24,991 NS | April 30, 2026 | N-PORT |
| WSML · iShares Trust | 0.07% | 5,742 SH | Aug. 8, 2026 | Daily |
| FHLC · FIDELITY COVINGTON TRUST | 0.06% | 41,183 NS | April 30, 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.05% | 196,549 NS | April 30, 2026 | N-PORT |
| UWM · ProShares Trust | 0.05% | 3,599 NS | May 31, 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0.05% | 2,419,186 SH | Aug. 8, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.05% | 275,155 SH | Aug. 8, 2026 | Daily |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.04% | 5,196 NS | April 30, 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.04% | 1,210,574 SH | Aug. 8, 2026 | Daily |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.04% | 112 NS | May 31, 2026 | N-PORT |
| URTY · ProShares Trust | 0.04% | 3,643 NS | May 31, 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0.02% | 5,689 NS | May 31, 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.02% | 3,773 NS | May 31, 2026 | N-PORT |
| HDG · ProShares Trust | 0.02% | 91 NS | May 31, 2026 | N-PORT |
| ITOT · iShares Trust | 0.01% | 146,419 SH | Aug. 8, 2026 | Daily |
| IWV · iShares Trust | 0.01% | 27,043 SH | Aug. 8, 2026 | Daily |
| DFAC · Dimensional ETF Trust | 0.01% | 125,853 NS | April 30, 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.01% | 3,342,704 SH | Aug. 8, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.01% | 8,345 SH | Aug. 8, 2026 | Daily |
| ESGV · VANGUARD WORLD FUND | 0.01% | 22,843 SH | Aug. 8, 2026 | Daily |
| ONEQ · Fidelity Commonwealth Trust | 0.01% | 28,694 NS | May 31, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.01% | 5,863 NS | April 30, 2026 | N-PORT |
| TILT · FlexShares Trust | 0.01% | 3,388 NS | April 30, 2026 | N-PORT |